Posters

Evaluation of bromfenac ophthalmic solution 0.9 mg/ml in prevention of macular edema following cataract surgery in diabetic patients

Poster Details

First Author: P.Pietro Elio ITALY

Co Author(s):    B. Francesco   W. Gualtieri           

Abstract Details

Purpose:

The purpose of this study was to evaluate bromfenac ophthalmic solution 0,9 mg/ml in the prevention of macular edema following cataract surgery in diabetic patients.

Setting:

C. Massaia Hospital, Asti

Methods:

This was a study of 60 adult type 2 diabetic patients ( HbA1c <7,5 % in 49 patients, HbA1c >8% in 11 patients) with mild to moderate nonproliferative diabetic retinopathy without macular edema, requiring cataract surgery. Patients were randomized (1:1) to instill bromfenac two times daily beginning 2 day prior to surgery for 15 days (30 patients, group A) or to instill bromfenac two times daily only 2 day prior to surgery (30 patients, group B). OCT (Zeiss Stratus OCT 3) was performed at baseline (≤28 days preceding surgery), 30 days post–cataract surgery.

Results:

A low percentage out of 60 patients developed macular edema, no case (0%) in group A, two case (6,6 %) in group B (Fisher's exact test ,SISA, GrapPad) Six patients (1 in group A, 5 in group B) had 20-25% increase in central subfield macular thickness from baseline. In these patient the HbAc1 value was >8.0% and torsional U/S mean power was more than in other patients for a dense cataract.

Conclusions:

This small case series suggests a benefit from topical bromfenac in preventing macular edema in diabetic patients following cataract surgery, with a good subjective and objective tolerability. In addition, hemoglobin A1c and U/S power delivery may have a role in determing macular edema following cataract surgery in diabetic patients. FINANCIAL DISCLOUSRE: NONE